Incyte Corporation (NASDAQ:INCY) has an average broker rating of 1.19, which is interpreted as a Strong Buy, as rated by 13 equity analysts. Nonetheless, 11 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. 1 other analysts advise a Buy. Nevertheless, the majority of 1 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold.
Incyte Corporation (NASDAQ:INCY) : Average target price received by Incyte Corporation (NASDAQ:INCY) is $93.6 with an expected standard deviation of $16.68. The most aggressive target on the stock is $135, whereas the most downbeat target is $76. 10 financial analysts are currently covering the stock.
For the current week, the company shares have a recommendation consensus of Buy. Also, BMO Capital initiates coverage on Incyte Corporation (NASDAQ:INCY). According to the latest information available, the shares are now rated Outperform by the analysts at the agency. The rating by the firm was issued on April 7, 2016.
Incyte Corporation (NASDAQ:INCY): stock turned positive on Tuesday. Though the stock opened at $73.41, the bulls momentum made the stock top out at $76.75 level for the day. The stock recorded a low of $73.41 and closed the trading day at $76.58, in the green by 5.72%. The total traded volume for the day was 1,208,885. The stock had closed at $72.44 in the previous days trading.
In an insider trading activity,The officer (EVP, Human Resources) of Incyte Corp, Swain Paula J sold 13,531 shares at $76.96 on January 15, 2016. The Insider selling transaction had a total value worth of $1,041,346. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Incyte Corporation is a biopharmaceutical company focused on the discovery development and commercialization of small molecule drugs to treat serious unmet medical needs. The Companys compound JAKAFI (ruxolitinib) also known as INCB18424 and INC424 is an oral Janus associated kinase (JAK) inhibitor used for the treatment for patients with intermediate or highrisk myelofibrosis (MF) including primary MF postpolycythemia vera MF and postessential thrombocythemia MF. The Company has a second oral JAK1 and JAK2 inhibitor LY3009104 (INCB28050) , which is subject to a collaboration agreement with Eli Lilly and Company in , which Lilly received development and commercialization rights f